脂质与他汀类药物与感音神经性听力损失:一项孟德尔随机化研究
本研究采用两样本孟德尔随机化方法,评估脂质及他汀类药物与感音神经性听力损失(SNHL)的关联。数据来自IEU OpenGWAS项目及FinnGen研究项目(32,487例SNHL患者与331,736例对照)。结果显示,遗传预测的较高甘油三酯水平与SNHL风险增加相关,遗传预测的阿托伐他汀使用与SNHL风险降低相关,瑞舒伐他汀显示出治疗SNHL的潜力但需进一步研究。
要点
- 遗传预测的较高甘油三酯水平与感音神经性听力损失风险增加相关。
- 遗传预测的阿托伐他汀使用与感音神经性听力损失风险降低相关。
- 瑞舒伐他汀显示出治疗感音神经性听力损失的潜力,但需进一步研究。
核心结论
- 研究提供遗传学证据表明,血液中甘油三酯水平升高可能是感音神经性听力损失的风险因素,而使用某些他汀类药物(包括阿托伐他汀和瑞舒伐他汀)可能降低感音神经性听力损失的风险。
研究设计与样本
- 本研究采用两样本孟德尔随机化方法;脂质与他汀类药物数据来自IEU OpenGWAS项目,感音神经性听力损失数据来自FinnGen研究项目,包含32,487例感音神经性听力损失个体和331,736例对照个体。
主要发现
- 遗传预测的较高甘油三酯水平与感音神经性听力损失风险增加相关。
- 遗传预测的阿托伐他汀使用与感音神经性听力损失风险降低相关。
- 瑞舒伐他汀显示出治疗感音神经性听力损失的潜力,但需进一步研究以阐明其与感音神经性听力损失的关系。
- 遗传预测的高密度脂蛋白胆固醇或低密度脂蛋白胆固醇水平或辛伐他汀使用与感音神经性听力损失相关的证据不足。
关键数值与推荐
- 根据牛津循证医学中心2011年证据水平分级,本研究证据水平为第三级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 瑞舒伐他汀与感音神经性听力损失的关系需进一步研究以阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent insights suggest that lipids and statin medication play a role in the development of sensorineural hearing loss (SNHL), yet the exact role remains controversial. This research applied Mendelian randomization (MR) to assess whether lipids and statin medication are associated with an increased risk of SNHL. METHODS: A two-sample MR was used in this study. Genetic instruments were constructed from variants associated with risk factors. Data for lipids and statin medication were obtained from the IEU OpenGWAS project, and for SNHL from the Finngen research project, which comprises 32,487 individuals with SNHL and 331,736 control individuals. RESULTS: Genetically predicted higher levels of triglycerides were associated with an increased risk of SNHL. The use of genetically predicted atorvastatin was associated with a lower risk of SNHL. Rosuvastatin has demonstrated potential in treating SNHL, yet further investigations are warranted to elucidate its relationship with SNHL. Insufficient evidence was available to suggest that the genetically predicted level of high-density lipoprotein cholesterol or low-density lipoprotein cholesterol or the use of simvastatin were associated with SNHL. CONCLUSIONS: The study provides genetic evidence suggesting that increased levels of triglycerides in the blood could be a risk factor for SNHL and that the use of certain statin medications, including atorvastatin and rosuvastatin, could reduce the risk of SNHL. These results align with findings from previous observational studies that have linked hyperlipidemia with the risk of SNHL. LEVEL OF EVIDENCE: According to the Oxford Centre for Evidence-Based Medicine 2011 levels of Evidence, the study has a third level of Evidence Laryngoscope, 134:4366-4373, 2024.
引用
- Wu H, Deng W, Luo Y, et al. Lipids and Statin Medication With Sensorineural Hearing Loss: A Mendelian Randomization Study. Laryngoscope. 2024. PMID: 38807496. doi:10.1002/lary.31500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。